Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas - Related Studies

Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas

This study has been suspended.

Study NCT00031083. Last updated on June 7, 2006. Information provided by Biogen Idec

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Glioblastoma Multiforme
		Anaplastic Astrocytoma
		Oligoastrocytoma, Mixed
		Gliosarcoma

2	Additional conditions recognized in this trial
		Astrocytoma
		Glioblastoma
		Glioma

3	More general conditions related to this trial
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Glandular and Epithelial
		Neoplasms, Nerve Tissue
		Neoplasms, Neuroepithelial
		Neuroectodermal Tumors

4	Interventions listed in this trial
		Interferon-beta

5	Additional drug interventions recognized in this trial
		Interferons

6	More general drug interventions related to this trial
		Anti-Infective Agents
		Antineoplastic Agents
		Antiviral Agents
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

7	Sponsors listed in this trial
		Biogen Idec